Arkema S.A. (AKE) Earnings Call Transcript & Summary
May 6, 2026
What were the key takeaways from Arkema S.A.'s May 6, 2026 earnings call?
Arkema S.A. reported its Q1 2026 earnings with revenues of EUR 2.2 billion, down 8.4% year-on-year, impacted by a 5.1% negative currency effect and a 3% decrease in selling prices. EBITDA reached EUR 283 million, slightly above expectations but down year-on-year due to currency impacts. Specialty Materials volumes increased by 1.5%, driven by strong demand in Asia. Management maintained its guidance for slight EBITDA growth at constant exchange rates for 2026, despite geopolitical uncertainties.
What topics did Arkema S.A. cover?
- Specialty Materials Performance: Specialty Materials volumes increased by 1.5%, driven by strong demand in Asia. Management highlighted a 15% volume increase in high-growth markets such as batteries and healthcare. "Batteries once again delivered strong growth," said Thierry Le Hénaff.
- Currency Impact: The depreciation of the U.S. dollar negatively impacted revenues by 5.1% and EBITDA by EUR 20 million. Management expects this impact to lessen from Q2 onwards.
- Geopolitical Challenges: The Middle East conflict affected supply chains and increased costs for raw materials and logistics. Arkema initiated pricing adjustments to offset these increases. "We remain agile in navigating this volatile environment," stated Le Hénaff.
- Advanced Materials Outlook: Advanced Materials experienced a slow start but is expected to improve in Q2, supported by High Performance Polymers. "Momentum improved in March and Q2 should be up sequentially," noted management.
- Coating Solutions Performance: Coating Solutions improved its EBITDA margin by 100 basis points due to a favorable product mix. Volumes were up 3%, driven by growth in Asia.
What were Arkema S.A.'s May 6, 2026 results?
- Revenue: EUR 2.2 billion (down 8.4% YoY, impacted by currency and price effects)
- EBITDA: EUR 283 million (slightly above expectations, up 14% QoQ)
- EBITDA Margin: 13% (Coating Solutions improved by 100 bps)
- Adjusted Net Income: EUR 65 million (EUR 0.86 per share)
- Net Debt: EUR 3.3 billion (Net debt to EBITDA ratio at 2.8x)
Arkema's Q1 2026 results demonstrate resilience amid challenging market conditions, with strong performance in Specialty Materials and effective cost management. The geopolitical situation in the Middle East remains a key risk, but management's proactive pricing and cost strategies provide some mitigation. Investors should monitor the resolution of geopolitical tensions and their impact on global supply chains and raw material costs as potential catalysts for future performance.
Earnings Call Speaker Segments
Good morning. The conference operator here. Welcome, and thanks for being with us on the Arkema First Quarter 2026 Results and Outlook Conference Call. Just a reminder that everyone is in listen-only mode, and following the presentation there will be a chance to ask questions by pressing star and one at any time. If anyone needs help during the conference call, they can signal an operator by pressing star and zero on their telephone. At this point, I'd like to hand the conference over to Mr. Thierry Le Hénaff, Chairman and Chief Executive Officer. Please go ahead, sir.
Thanks so much. Morning, everyone. Welcome to the conference call covering Arkema's Q1 '26 results. With me today are Marie-José Donsion, our CFO, and the Investor Relations team. As usual, we've posted a set of slides to support this call, and they're available on our website. I'll walk through the quarter's highlights before handing over to Marie-José for the financials. Once the presentation wraps up, we'll be available, as always, to take your questions. Carrying on from 2025, market conditions stayed soft through January and Feb 2026, then improved in March. Regional trends differed, with demand still subdued in Europe and the US, while Asia again showed solid momentum across several of our end markets. On top of that, the quarter was once again hit by the depreciation of the US dollar versus last year, though this impact should be more limited starting in the second quarter. At the end of February, the conflict in the Middle East broke out, which began to affect global supply chains and quickly drove a sharp rise in certain raw materials as well as energy and logistic costs, starting in Asia. Against this complex backdrop, Arkema delivered volumes that were stable year-on-year — a solid performance given the circumstances.
Specialty Materials played a big part here, with volumes rising 1.5%, helped by a strong rebound in March. Every segment within Specialty Materials posted gains. Coating Solutions drew clear benefit from improved conditions in UV-curing resins. Advanced Materials delivered solid growth across key attractive markets for High Performance Polymers. Adhesives got a lift from durable goods along with a modest improvement in construction. This volume result also mirrors Arkema's ongoing momentum in high-growth pockets, as volumes climbed 15% across attractive end markets including batteries, sport, 3D printing, and healthcare. Batteries again posted strong growth, backed by the swift expansion of energy storage systems — a key additional driver for the group, especially within High Performance Polymers. Consequently, Q1 EBITDA landed slightly ahead of expectations at €283 million, 14% higher than the fourth quarter of 2025, aided by an improvement in March. Even so, EBITDA declined year-on-year, mainly hit by a significant negative currency effect of roughly €20 million and the lack of any rebound in the US and Europe thus far. In addition, Advanced Materials saw a slow start to the year, consistent with the trend seen in Q4. Momentum did improve in March, though, and Q2 should rise sequentially, helped by HPP.
I'd also like to highlight how well Coating Solutions did — its EBITDA margin rose 100 basis points, helped along by a more favorable product mix. Adhesive Solutions posted a significant improvement from the prior quarter, even though it was down year-on-year. Primary Materials, meanwhile, saw earnings edge up slightly year-on-year, largely on the back of legacy refrigerants in the US. In acrylics, spreads in Asia began improving late in the quarter, so the effect was only limited, and conditions in Europe and the US stayed challenging, especially in January and February. That said, looking ahead from where we stand today, it's reasonable to expect acrylics spreads to improve in Q2, though the magnitude is still to be confirmed. As you'd imagine, every team is fully mobilized to handle the current economic and geopolitical challenges effectively and swiftly. During the first quarter, we offset fixed cost inflation at constant currencies, and we remain well on track to meet that goal for the full year, backed by a number of cost-cutting initiatives. As for the Middle East crisis, the group is responding quickly to limit supply chain disruptions, both when it comes to raw material availability and, more importantly, input cost inflation.
We've begun making pricing changes to counter higher costs for raw materials, energy, and logistics, rolling them out selectively depending on the product market and geography. That effort has demanded tight, ongoing coordination with suppliers as well as customers. The price increases will start showing up in Q2. It's worth noting that Arkema's geographically balanced setup — serving customers mainly from their own region — is a genuine advantage in today's conditions. So far, we've managed to steer through this crisis with no disruption to supply. On top of that, Arkema stayed focused on delivering its key growth projects. Right now the group is wrapping up its new PVDF capacity in the US, due to come on stream mid-year. That will bring 15% more capacity in the region, addressing rising demand for locally made PVDF, especially for energy storage systems, semiconductors, or cable applications. At the same time, the group announced another 20% capacity expansion at its PVDF plant in China, set to begin in 2028. In addition, the new Carling unit, downstream of our PA11 in Singapore, came on stream successfully at the start of the year and should underpin HPP earnings momentum from Q2 onward, powered by capacity ramp-up. I'd also like to highlight PIAM's strong first-quarter performance.
EBITDA rose over 30% versus a year earlier in local currency, and the EBITDA margin came in at 35%. As we pointed out on our previous call, PIAM is still gaining from strong momentum — helped especially by solutions aimed at foldable and ultra-thin smartphones, along with its move into higher-end applications. That favorable trend should carry over into the second quarter, with solid sales growth compared with a year ago. On top of that, Arkema remained disciplined when it came to capital allocation. We turned in a solid performance on working capital management. That helped recurring cash flow land above last year's level. The result also mirrors reduced CapEx, which is entirely consistent with our €600 million target for full-year CapEx. At this point I'll pass things to Marie-José, who will take a closer look at the financials by segment before we turn to the outlook at the close of the presentation.
Thanks, Thierry, and good morning to all of you. Arkema's first-quarter revenues came in at €2.2 billion, which represents an 8.4% decline versus the same period a year ago. A negative currency effect of 5.1% weighed on those sales, driven principally by the US dollar having weakened against the euro relative to Q1 of last year. Volumes were broadly flat compared with a year earlier, helped by a robust March following a fairly slow beginning to the year. The price effect stood at a negative 3%, essentially mirroring the softer selling-price environment relative to Q1 2025, consistent with the gradual decline in raw material costs seen during 2025. Q1 EBITDA reached €283 million. Currency movements accounted for a hit of roughly €20 million. Turning to segment performance, Adhesive Solutions posted EBITDA of €89 million. Beyond the currency drag, that reflected demand that remains weak in North America and Europe. Volumes edged up modestly, let's say, on an overall basis, with Asia providing most of the support. The segment's results were led chiefly by adhesives for durable goods, helped by gains in aerospace and heavy truck markets in North America. Packaging, by contrast, stayed soft, while construction showed better momentum, particularly in Europe. For Advanced Materials, EBITDA was €139 million. Excluding currency movements, an unfavorable mix of products and geographies was essentially what weighed on that EBITDA.
For a big chunk of the quarter, market conditions looked a lot like what we saw in Q4 of last year. That means demand stayed soft in the US and Europe, while Asia kept up its positive momentum. Against that backdrop, Coating Solutions turned in a solid performance, with EBITDA holding steady year over year at €51 million. Volumes rose 3%, mainly on the back of strong growth in Asia, especially in UV-curing resins. The EBITDA margin came in at 13%, up 100 bps, helped by our push into higher value-added applications. Finally, Primary Materials EBITDA was up slightly at €33 million, supported in particular by a good showing in legacy refrigerants in the US, while acrylic monomers remained in low-cycle conditions through most of the quarter. Depreciation and amortization was €165 million, which brings recurring EBIT to €118 million and a REBIT margin of 5.4%. Non-recurring items totaled €45 million. That figure includes €34 million of PPA depreciation and €11 million of one-off charges, notably some restructuring and reorganization costs. Financial expenses were -€29 million, and the increase from last year mainly reflects the cost of carry on the pre-financed green bond issued at the end of 2025. As a result, Q1 adjusted net income came to €65 million, equal to €0.86 per share.
Turning now to cash flow and net debt: recurring cash flow in Q1 came in at -€95 million, and that figure reflects the usual first-quarter classical working capital seasonality. On annualized sales, the working capital ratio is 16.3%, an improvement versus a year ago. Capital expenditure for the quarter totaled €75 million, which again aligns with the guidance we've given for annual CapEx of €600 million across the full year 2026. At the close of March '26, net debt and hybrid bonds stood at €3.3 billion. Our net debt to last twelve months EBITDA ratio is 2.8 times. Thanks for listening, and I'll now pass things to Thierry for the outlook.
Thank you, Marie-José. As you can see, even with geopolitical headwinds, we managed to achieve positive volume growth in our Specialty Materials segment during the first quarter, including a double-digit rise in our key attractive markets. Moving into the second quarter, the conflict in the Middle East, which started 2 months ago, is still ongoing, with continuing uncertainty about its direction and its duration, sorry, and how large its consequences will be for the global economy. At this point, obviously, the group's key priority is staying agile while navigating this volatile environment and adapting its pricing policy quickly to offset input cost inflation. That is clearly what we are doing. Like everyone, we remain attentive to other potential impacts of this context, notably on global demand. At the same time, this crisis could also generate some upside, since it could also temporarily lead to a tighter supply-demand balance in certain value chains. In parallel, the group continues to focus on self-help measures, maintaining tight cost and operational control, as you could see in the in the first quarter, alongside the disciplined execution and the ramp-up of its growth projects. In this context, the group confirmed its target of a slight EBITDA growth at constant exchange rate for 2026.
Before we start the Q&A, I'd like to say a brief word about Arkema's journey over the last 20 years. We've added a few slides to the deck marking this anniversary. The company listed on May 18th, 2006, and in just a few days we will be celebrating the group's 20th anniversary. During this stretch, the company has been through a deep and unique transformation: from a mix-bag of commodity businesses — most of them unprofitable at the time, and most of them centered on Europe — into a global and profitable leader in Specialty Materials. Today, Arkema also benefits from a strong financial structure, solid performance, and it meets high non-financial standards as well, while offering customers a superior set of cutting-edge technology. The chemical industry is currently in a low cycle, which shows up in the share price and leaves room for significant upside ahead, yet over 20 years Arkema has delivered strong long-term value creation. €1 invested in Arkema in May 2006 has become €3.6 today, including dividends. On top of that, the rise in Arkema's share price over these 20 years is well above the evolution of the CAC 40 and its chemical peers, particularly in Europe. Thank you very much for your attention — together with Marie-José, we are now ready to take your questions.
Thanks. This is the conference operator. We'll now start the question and answer session. If you'd like to ask a question, you can press star and one on your touch-tone telephone. To take yourself out of the question queue, please press star and two. Please pick up the receiver when asking questions. Anyone who has a question may press star and one at this time. The first question comes from Tom Wrigglesworth, Morgan Stanley.
Hello, Thierry and Marie-José. I really appreciate the presentation. If I may, I have two questions. In the first quarter, we saw stronger volumes in the more specialty side of the business and weaker volumes in the more upstream side, yet your remarks about supply and demand chains tightening would imply the opposite is about to occur. Should we be expecting that, and could you share how you think this will unfold for 2Q and for the remainder of the year, perhaps on a regional basis too, since we anticipate fairly varied results between, for instance, Asia and the US? I'd be very eager to hear your perspective on this. My second question, which is related and follows on, is: what do you believe the medium-term, more structural or more sustainable effects will be — or what are you already observing in customer behaviors — stemming from the conflict that has arisen in the Middle East? Thank you.
Thank you, Tom, for that question. Clearly, we're operating in an interesting world where nobody can say with certainty what lies ahead. Visibility is still limited. The positive side — and this is certainly what you can take from the Q1 performance as well as from our comments and the full-year — is that we remain solid, since we have a portfolio that is balanced both geographically and in terms of product lines. Diversity can sometimes deliver stability, and that is exactly the case for Arkema. Coming back to your question, I'd say the dynamics from a geographical perspective will keep showing the same contrast through Q2 and possibly the rest of the world, with the engine clearly being Asia more than Europe and the US. We'll see. From a product line perspective, it may vary from one month to the next. What's clear is that, as we said, acrylics — which is what we referred to as upstream — will benefit in Q2, at least from an improved supply-demand balance. Last year, I think, we clearly suffered in acrylics; in Q2 we will see light in the tunnel, which is good, and which shows that our strategy is delivering benefits and that the diversity of the portfolio is playing its part.
As I said a couple of months back — this was during the early phase of the Middle East crisis — I stated my view that this crisis would bring both positive and negative effects, yet on balance, for Arkema, it ought to be roughly neutral. That thinking still holds, which is why we reaffirmed the guidance for the full year. You brought up upstream, but take coatings: we're seeing decent momentum there, a reversal from last year in the Q1 quarter, and that should be confirmed in Q2. As for adhesive, it's a kind of overall resilient solidity — not wonderful, but resilient on the whole. In Advanced Materials, I'd say there's more contrast, because we believe that in HPP, following the soft start I mentioned, we should begin to see a sort of sequential momentum, gaining from all those key projects we've cited along with new investments, whereas on the other side, Performance Additives may end up the loser from the Middle East crisis, since this business, this product line, has the largest number of customers in the Middle East, and is certainly more affected by raw material increases such as sulfur, where a time lag exists before you can pass it on to customers.
I'd say the portfolio is going to contribute across the board. Ultimately, what's good about what we deliver is that nothing catches you off guard in a world with plenty of unknowns—there are some positives and negatives, but on the whole it's kind of neutral stability, though clearly there's plenty of work for the team. Now, on the medium-term effect from the Middle East crisis—which, I imagine, your question is about global demand—I'd say nobody knows for sure. If it drags on for a long time, there certainly should be an impact, given inflation and the disruptions. So far, we aren't seeing too much. Volumes are correct. I'd say not worse than last year, not at an extraordinary level, but I'd say not too much impact so far. Wait and see. We confirm—I think, taking everything into account, we believe that for Arkema, this Middle East event should be neutral, with some positive element and some downside.
To build on that point, should we anticipate EBITDA for 2Q '26 coming in higher than what we saw in 2Q 2025? I'm simply looking for a benchmark of some kind so I can grasp how this could unfold.
My sense is that this was taken into account when we set the full-year guidance. If you recall, last year we were more in the range of -25% versus the prior year, particularly in H2 and Q4. We then came in at -14% in Q1. You can see that, step by step, we are closing the gap with last year on a year-on-year basis. I would say we ought to be comparable — I would say Q2 '26 versus last year — which would represent a significant step up, and that is really our roadmap for delivering the full-year guidance. By achieving that, we would be really aligned with the full-year guidance.
That's very clear. Thank you, Thierry. I appreciate you sharing your thoughts.
Matthew Yates from Bank of America has the next question.
Hey, good morning, everyone. I wanted to ask about the Advanced Materials division, starting from the margin you currently have and the trajectory to get towards the midterm guide, and in particular, the point on mix. I'm not sure I fully understand why mix is a headwind at the moment. Maybe there's some specific products, but you alluded to geographic mix, and I'm struggling to reconcile that with the idea that your CapEx has been disproportionately in Asia to satisfy where the demand is coming from. Yet somehow mix is negative. I wouldn't have intuitively assumed that the Asian demand was going to be margin-dilutive, or else that wouldn't be consistent with the mid-term targets. Can you just explain to me what's been going on with mix and how you see that evolving? Then somewhat related, you've announced an incremental investment in PVDF in China. There's been a lot of debate in recent years about the degree of competition and commoditization. I see one of your peers in Japan recently took a large write-down on some investments they're making. Why do you still believe that you can make a reasonably attractive return in that PVDF segment and it warrants putting more capital into it?
Thanks.
Matthew, thank you. That's a genuinely intriguing question, and I'd say it's of an entirely different character. Really, when we look at the bigger picture over the medium term, we feel good about the fact that both our geographic and product mix will get better. That isn't what the near term is about, though. What drives the near term is almost mechanical, I'd argue. The reason is that unit margins in Europe and the US are inherently higher across many of our businesses than they are in Asia — that holds true for lots of companies. The underlying cause is that the cost structure itself is heavier in Europe and the US than in Asia. Ultimately, when it comes to profitability, we actually have fairly strong profitability in Asia, just as we do in the US; in Europe we're lower. What that means is that at the same volume, when those volumes carry more weight — which has been the case for 2 years in Asia, since that's where our growth is — in fact, for the same fixed cost in each region, you get less margin on a given volume in Asia than you do in Europe and the US. Right? So in EBITDA terms, EBITDA is, let's say, comparable everywhere, but unit margins are lower in Asia than they are, while the EBITDA margin is comparable.
So that means when you’ve got higher volume and more development in Asia, it drags down the average mix against the same fixed cost; it drags down the EBITDA margin. It’s almost mechanical, actually. Right? Then, if you take a longer view, Europe and the US—we’re confident about that—we get volumes back, okay, and gradually, it will return. We confirm—in fact, we’re very glad to confirm the midterm target for Advanced Material, which would be well above 20%, but this is purely what we explain with the mix. As for the product mix, I’d say no, because if I set aside that geographical discrepancy, product-wise, we develop the product that carries a higher margin. Again, even by themselves, they earn more unit margin in Europe and the US than they do in Asia. Now, regarding the PVDF investment in China, which is for Asia—it’s not only for China, it’s for Asia—it’s really very consistent with our strategy for several years. We’ve had a lot of questions about this PVDF. We have to say that PVDF, for many years and still today, is an engine of growth and profitability for the company, and we want to develop it globally.
We’ve got this investment in the US, and we’ve got this investment in China, and we feel quite confident that this investment will pay back quite well. Now, Korea — I don’t know; that’s, I’d say, their subject, their profile. As for us, we’re very comfortable with what we’re doing, and that demonstrates that the quality of our innovation in PVDF, the positioning, and the fact that we truly concentrate on the high end of the range are paying off. It could be in semiconductor, it could be in batteries, it could be in cables. I believe we have a solid and differentiated strategy in PVDF.
Thierry, let me just add one follow-up question. Regarding what you said about this business in Q2, is the story that certain specific projects are ramping — foldable phones came up in the intro, for instance — and those carry very high margins, or is it simply that better volumes overall lead to improved fixed-cost absorption?
We received a handful of messages since we made those comments. I concur regarding HPP and Advanced Material. Actually, what we said was—Q1 was, and this ties to some degree to your first question. From our perspective, within the mix at Arkema, Advanced Material in Q1 was perhaps the letdown. The point we wanted to make was: fine, it's a slow beginning, but things will build through the second quarter, at minimum on a sequential basis. We see solid business potential from the big project, and that big project relates to HPP, and it was also meant to highlight the mix in Advanced Material during Q2 across HPP and Performance Additives, with HPP showing, shall we say, favorable gross momentum, PIAM included, which as you noted is performing quite well, but past PIAM, with PVDF and so on, plus polyamide and specialty fluorogas. Conversely, Performance Additives is taking a hit from the Middle East, since that business line of ours sells the largest share into the Middle East, and they face this sulfur issue. This is mainly to offer you some detail within Advanced Material, which will feature, shall we say, two contrasting business lines for the quarter.
Following that, it has the ability to change. All right?
Thanks, Thierry.
On the positive side — and maybe just to add to that — our big projects are gradually ramping up, one step at a time, and as you're aware and as we've said many times, this will have an impact on HPP in both the short and long term.
James Hooper from Bernstein has the next question.
Morning, everyone. For the first question: Thierry, you mentioned in your answers the geographic mix, which leans more toward Asia and is weaker in Europe and North America. Given the US PMI trajectory, or what we've seen on the oil price and elsewhere since the conflict began, do you expect that to shift? Second, may I ask about March as well? It was clearly stronger than expected. Do you believe any of that reflected customers buying ahead, and perhaps Asia was particularly strong, which tends to be the spot market and where you see perhaps the most current capacity outages? Thank you.
Thanks for asking that. On geographic mix, I’d say yes — we have faith in the US, since we put a lot of investment there. It accounts for 35% of our sales, and from a competitive standpoint we think their competitiveness is superior, particularly when it comes to energy, and what’s happening in the Middle East only reinforces that. We think the US has plenty of ingredients for this economy to rebound at some point. That isn’t what we’re seeing today. It hinges on whether your question is short term or long term. In the short term, we need to be cautious, and we still see these dynamics coming from Asia. Now, “reverse” isn’t really the right way to put it, because that would imply Asia would get down, which wouldn’t happen — rather, it would rebalance with the US getting stronger. We’re at a low point in many of our businesses in the US. We’re starting to see a little bit of green shoots. They’re minimal here and there, which maybe could make us feel that over the course of the year we should see some improvement, but right now there are so many elements in the geopolitics that we have to be careful.
On the March question, there could be some pre-buying, perhaps more in the upstream parts of our businesses, possibly. Now, looking at March volume, for the company as a whole we're at par — not for March specifically, but for the quarter, versus last year. If you add January plus February plus March, we tend to examine the full quarter with varying dynamics, a slow start and then some offset or catch-up in March. There's certainly a bit of pre-buying. For instance, looking at April — I believe we said this in the press release, or I think April continues the pattern of March, which is also part of the answer. What that means is the solid March we're seeing carries on into April. We need that in order to deliver a Q2 in EBITDA comparable to last year.
Thanks, Thierry.
Our following question comes from Laurent Favre at BNP Paribas Exane.
Yes, good morning. My question concerns the downstream businesses, and I suppose it centers on net pricing. I was wondering whether you could discuss, for the large categories of adhesives, coatings, and the rest, what you are currently observing when it comes to raw material inflation? Are we talking mid-single digits, low double digits, perhaps high teens inflation? Are surcharges being used, or do you expect to see, I suppose, pricing that matches this kind of inflation? When you mention short-term squeezes on downstream, does that mean a few quarters, or merely a few weeks and months?
All right. When it comes to raw materials, I'd say this applies across the whole company, not only to the downstream businesses — you're seeing raw material increases that can run anywhere from a few percent up to 100%. It's happening really fast and really sharply. That's why our teams — who, unfortunately, already had the training from what we went through during COVID — are moving very quickly to push through price increases. Now, it's obvious, and you know this very well from your own experience, that passing costs on to customers happens faster upstream than it does downstream. Our sense is that the further downstream you go, the more the full quarter will be needed to pass everything through. Our plan, I'd say, is to do it immediately, by the end of the quarter. Because we have some businesses — the more upstream ones — that will see some upside effect, as is the case with acrylics this quarter, that will fully offset the time lag we may have on the more downstream businesses. That's where the strength of our portfolio diversity comes into play. Overall, we should be in good shape. Now, it's clear that you get different colors depending on where you sit, from upstream to downstream, within the quarter.
The goal is to complete the entire task by quarter end. The reason a bit of a delay exists is that customer profiles can differ enormously—even their own limitations vary. That's why, just like in real life, it takes some time. On top of that, the raw material cost increases keep arriving one after another. So you have to go back and say, alright, it's higher, we need to pass along more, and so on. That's real life. Broadly speaking, this is why we made a point of commenting on EBITDA compared with last year in Q2—because we think that with our portfolio there will be some positives and some negatives, but overall we can handle it. It's work that demands a great deal of energy from our teams, as I'd imagine it does for everyone.
Thank you. If we look back to 2022, pricing was extremely robust—even in downstream segments—and that came at the cost of volumes. My recollection is that you said at the time there were particular volumes you were glad to give up, since they carried lower quality and thinner margins. Does any of that apply today, or are you at this point pursuing every molecule, viewing them all as high quality and wanting to hold on to that volume?
Obviously, when you're leaning heavily on raising prices—particularly in a world dealing with war—we shouldn't lose sight of the fact that, in the Middle East, that isn't what will drive volume up in any significant way. Let's put it this way: our target is roughly flat volume, okay, and within that flat-volume guideline, or context, we push price. Right? It's not quite the same as after COVID, when we still had to rationalize our portfolio, especially in adhesive, where that work has already been completed. Okay? Things are more stable now, but let's say flat volume, and then we focus on pricing.
All right, thank you so much.
Our next question comes from Jaideep Pandya at Onfield Research.
Thank you. There are three things I'd like to ask about. The first concerns acrylic acid. Honestly, if you look at this product in Europe and the US, no capacity has been added there for quite a while, yet margins have kept sliding lower over time. So with the war as a backdrop and naphtha and propylene being tight in Asia, what's your view on the medium-term picture for acrylic acid? Given that some markets, India being one example, are becoming increasingly self-sufficient, do you believe capacity rationalization is needed in Europe or the US? That's my first question. My second one is about sulfur. With sulfur in short supply, how do you view the upstream methionine market — or, from where you sit, the mercaptans value chain? Have you managed to gain market share, or is this a problem at the moment in your view? My final question concerns PA11. Clearly, you've invested very heavily in Singapore. Comparing the Singapore plant as it stands today with your French plant, on both operational performance and profitability, where are we right now?
So would you say product output is roughly on par now, but profitability hasn't caught up yet — or where do we stand on that? Thanks a lot. Okay.
On acrylic acid, first, we're glad to see some improvement after the couple of challenging years you referenced, and we recognize that this matters a great deal for the team, and it isn't coming at the expense of the downstream, which is a positive. Because you saw how Coating Solutions performed in Q1, which is on par with the prior year, even if that prior year wasn't great, I'd say. This is a chain that is solid at the moment. Now, as we said, on the tightness, we have no crystal ball. I think we're cautious because we've just come out of 2 years in which acrylics were really under pressure. We think that clearly with the conflict, and maybe hopefully past the conflict, we'll stabilize around a more normalized spread. Let's take it step by step. The first step is to do our job in a market that has changed notably with the Middle East crisis, and we'll see how long this crisis lasts. It's a big parameter, and nobody knows about it. After that, we'll see where we stand and we'll certainly adapt. I think the good news is that we benefit from this diversity of the portfolio, with some more upstream business and some really downstream businesses.
Regarding sulfur and methionine—we aren't in the methionine business itself. I'd say we supplied our customers, and that market share question is really more their subject than ours. What we do on our side is supply them as well as we possibly can. As for sulfur availability, we're managing. That's good news. Sulfur costs have risen a great deal now, and our focus is on raising prices, which is where contract timing creates some lag for us. Not all markets are alike, but I'd say we do find the sulfur. On Singapore, first of all, the good news is that the plant there is operating very well. It took years, as you know. We began from a low point, learned a great deal, and today it's truly a very, very good plant, very, very optimized. Next to Marseille, it is more modern and ought to be more profitable. On the other hand, its capacity is smaller than Marseille's. All in all, I'd say the two are comparable—that's my answer to your question.
Alright, thanks.
At this point, no further questions are in the queue. I'll hand things back to management for any closing comments.
Since there are no further questions, I really appreciate everyone's time today. As always, feel free to reach out to the IR team if you need anything filled in from my responses. I hope everyone has a great day.
Thank you, everyone, for being here. That brings this conference to a close. Please go ahead and hang up your phones.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Arkema S.A. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Arkema S.A. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.